Profile data is unavailable for this security.
About the company
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
- Revenue in HKD (TTM)970.97m
- Net income in HKD-387.39m
- Incorporated2017
- Employees574.00
- LocationAscentage Pharma Group International68 Xinqing Road, Suzhou Industrial ParkSuzhou ChinaCHN
- Websitehttps://www.ascentage.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman Ltd | 534.69m | -17.42m | 2.96bn | 275.00 | -- | 1.33 | 831.65 | 5.53 | -0.0295 | -0.0295 | 0.8233 | 3.28 | 0.2159 | -- | 65.75 | 2,072,427.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 405.36k | -402.56m | 3.15bn | 150.00 | -- | 4.88 | -- | 7,771.80 | -1.12 | -1.12 | 0.0011 | 1.72 | -- | -- | -- | 2,795.62 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
| CARsgen Therapeutics Holdings Ltd | 6.82m | -747.16m | 4.21bn | 477.00 | -- | 2.64 | -- | 617.90 | -1.34 | -1.34 | 0.0122 | 2.80 | 0.0027 | -- | 0.302 | 13,211.24 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
| Alphamab Oncology | 275.12m | -231.85m | 4.41bn | 429.00 | -- | 2.52 | -- | 16.02 | -0.2408 | -0.2408 | 0.2858 | 1.81 | 0.1145 | 0.8256 | 13.94 | 632,461.60 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
| Lepu Biopharma Co Ltd | 220.51m | -78.09m | 5.47bn | 491.00 | -- | 5.57 | 402.06 | 24.82 | -0.0463 | -0.0463 | 0.1325 | 0.575 | 0.0847 | 1.86 | 1.53 | 514,013.20 | -3.53 | -- | -5.72 | -- | 78.76 | -- | -41.62 | -- | 0.7322 | -2.71 | 0.4621 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| Laekna Inc | 0.00 | -317.77m | 6.13bn | 92.00 | -- | 8.43 | -- | -- | -0.8917 | -0.8917 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
| TYK Medicines Inc | 0.00 | -460.14m | 10.75bn | 144.00 | -- | -- | -- | -- | -1.24 | -1.24 | 0.00 | -3.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -50.25 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| Keymed Biosciences Inc | 87.80m | -798.98m | 11.19bn | 1.12k | -- | 3.95 | -- | 127.45 | -3.06 | -3.06 | 0.3358 | 10.13 | 0.0207 | 0.3115 | 7.74 | 97,877.70 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Ascentage Pharma Group International | 970.97m | -387.39m | 13.33bn | 574.00 | -- | 16.15 | -- | 13.73 | -1.34 | -1.34 | 3.34 | 2.62 | 0.2998 | 3.49 | 2.19 | 1,665,471.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Genscript Biotech Corp | 7.86bn | -1.38bn | 22.87bn | 7.28k | -- | 2.41 | -- | 2.91 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,728.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Data as of Nov 22 2024. Currency figures normalised to Ascentage Pharma Group International's reporting currency: Hong Kong Dollar HKD
6.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 8.49m | 2.69% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 3.00m | 0.95% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 2.13m | 0.68% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.77m | 0.56% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 1.48m | 0.47% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.23m | 0.39% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2024 | 977.40k | 0.31% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 871.20k | 0.28% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 542.96k | 0.17% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 503.80k | 0.16% |
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
